Our History 2018-01-21T16:34:41-07:00

December 2020

Boyalife is awarded as 2020 China’s New Health Enterprise

April 2020

ThermoGenesis receives acknowledgement letter from FDA allowing Its SARS-CoV-2 (COVID-19) IgM/IgG antibody fast detection kit for distribution.

December 2019

Boyalife’s stem cell bank in Tianjin officially operates

April 2019

Boyalife join hands with Bureau of Science and Technology of Wuxi Municipality to launch the cell therapy industry alliance initiative

April 2019

Boyalife signs a framework agreement for regenerative medicine with Wuxi People’s Hospital.

November 2018

Boyalife’s cutting-edge technology unveils at the Xi’an Global Hard&Core Technology Industry Expo 2018

July 2018

Boyalife wins the title of “The Most Potential Venture High-tech Company of Technological Talent Entrepreneurship”

March 2018

ThermoGenesis Crop entered the market of  CAR-T  Related Contract Development and Manufacturing (CDMO) Services.

November 2017

Boyalife signs a formal agreement with Fujita Health University to build the Fujita-Boyalife International Research Center for Regenerative Medicine in Japan.

July 2017

Cesca Therapeutics, a Boyalife company, acquires SynGen to expand its capabilities in the processing of high-value target cells.

March 2017

Boyalife establishes the ThermoGenesis Corp. subsidiary under Cesca to further strengthen its device business.

November 2016

Boyalife treats the world’s first case of Cockayne Syndrome through the use of placenta-derived stem cells.

June 2016

Boyalife Group establishes a global award, the Boyalife Science Translational Medicine Award in Stem Cell and Regenerative Medicine.

May 2016

Boyalife Group acquires 17% ownership in Nuo Therapeutics Inc. (NASDAQ:AURX)

February 2016

Boyalife Group acquires 70% equity ownership in Cesca Therapeutics Inc. (NASDAQ:KOOL), a US-based leader in automatic cellular processing and autologous cell-based therapies.

January 2015

Boyalife Group wins the National R&D Leadership Award. Boyalife Genomics opens a cloning facility in Tianjin for cattle breeding.

December 2014

Boyalife Group obtains a seat on the board of Sooam Biotech Research Foundation.

September 2014

Boyalife Genimics clones the first Chinese Tibetan Mastiff.

December 2013

Chairman Dr. Xiaochun “Chris” Xu wins the 2013 China Economic Figure Award.

November 2012

BoyaLife Group wins the Prestigious 2012 CCTV China Brand Award.

July 2012

Peking University and Boyalife jointly form the PKU-Boyalife Institute of Translational Medicine.

May 2012

Peking University acquires a 40% position in Bejing Boyalife Stem Cell.

December 2011

Dr. Ruiping Xiao, the founding director of the Institute of Molecular Medicine at Peking University (IMM-PKU), became a chief scientist of INCOSC.

September 2011

Boyalife signed a strategic partnership agreement with the Institute of Molecular Medicine at Peking University.

August 2010

Boyalife Stem Cell Bank was established and accredited by NRL and CAP. It has become the #1 recognized brand by stem cell professionals in China.

July 2009

INCOSC was founded and supported by several major grants from the Chinese Ministry of Science & Technology (MOST) and local governments to foster collaborations among a number of top universities and research institutes. INCOSC later evolved into the Boyalife Group.